The National Psoriasis Foundation (NPF) is developing an agenda for patient-centered research to help patients and their caregivers make more informed health care decisions by engaging psoriasis patients in prioritizing comparative effectiveness research (CER) topics. The NPF has created a novel patient-centered research platform known as Citizen Pscientist (CP), allowing patients with psoriasis and psoriatic arthritis to register and contribute their health data. The CP Governance Council administered an online 23-question CER survey to the CP community and held a structured meeting on December 3, 2016, with patients and researchers to review CER survey results and discuss patient-centered research priorities. Of the 2,945 patients surveyed, 792 patients responded. Three CER topics were deemed to be of high priority for the research agenda: 1) Treat-to-target therapy for psoriasis, 2) Psoriatic arthritis screening questionnaires for early detection and treatment of psoriatic arthritis, and 3) Comparative effectiveness of home-based phototherapy for psoriasis.
INTRODUCTION
Over the past two decades, the National Psoriasis Foundation (NPF) has been engaged in supporting a variety of research initiatives. A current priority for the NPF is developing an agenda for patient-centered research, which is research that is highly relevant to patients, and helps patients and their caregivers make informed health care decisions. Such research may be facilitated by patients who develop research ideas, design and participate in research, and perform research themselves. The patient perspective is vital to identifying research initiatives that matter to patients and may facilitate improved health care outcomes.
Along with patient-oriented research, the NPF aims to engage psoriasis patients in prioritizing comparative effectiveness research (CER) topics. The NPF has previously been engaged in CER through funding (RC1-AR058204) it received from the National Institutes of Health to participate in the Dermatology Comparative Effectiveness Research Network (DCERN). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] CER aims to compare the effectiveness of treatment strategies or ways to deliver health care in a real-world setting, ultimately generating evidence that will inform health care decisions. Although randomized controlled trials (RCTs) are the gold standard for clinical trials, they are limited in their external validity as a result of strict inclusion criteria, short duration, and unrealistic settings for patient care, 11 and thus only measure idealized treatment efficacy. The alternative measure of effectiveness refers to performance in real-world conditions outside the ideal settings of an RCT, 12 citizenpscientist.com) allows patients with psoriasis and psoriatic arthritis to register and complete a questionnaire contributing their health data, including demographics, psoriasis subtype, psoriasis severity, triggers, and response to treatments. The anonymized data are stored in a cloud database, and patients can explore the data by testing their own hypotheses and making discoveries. These findings can be graphed and posted in the discussion forum to generate ongoing dialogue among the CP patient community. CP can identify areas of patient research interest by examining popular and trending discussions among patients.
Additionally, once validated, the data can serve as a rich database for psoriasis and psoriatic arthritis researchers.
Overseeing the CP project is the CP Governance Council, composed of NPF research staff, patients with psoriasis and psoriatic arthritis, and researchers.
To better understand patient-centered research priorities and create a patient-centered research agenda, the CP Governance Council administered an online CER survey to patients in the CP community and held a structured meeting with patients and researchers to discuss these topics in person. The questions were randomized to prevent any bias and influence of order on responses. 
METHODS

CER Survey
Patient-Centered Research Meeting
On December 3, 2016, the NPF held a meeting with the Citizen Pscientist Governance Council and other stakeholders in Dallas, where patients and researchers reviewed CER survey results and jointly developed a roadmap for patient-centered research in psoriasis and psoriatic arthritis. A roster of meeting participants is shown in Table 2 . The meeting structure involved a presentation of the CER survey results followed by a group discussion to identify CER priorities.
Attendees were asked the following two questions: 
Discussion of potential research priorities among meeting attendees led to high interest in the topics of the efficacy of methotrexate versus biologics in psoriatic arthritis, the treatto-target approach, comparative effectiveness of home vs.
office-based phototherapy, personalized medicine studies, benefit/risk ratio studies, and complementary medicine treatment approaches. Many of these priorities overlap with the primary themes identified by patients in the CER survey. Other CER priorities identified by the group include comparing the effectiveness of biologics with one another, determining the inf luence of patient support groups/ assistance programs on patient outcomes, and research on patient outcomes when using prevention and screening protocols for psoriasis co-morbidities.
DISCUSSION
Results from the CER survey highlighted important themes regarding screening and treatment for psoriatic arthritis and treat-to-target for psoriasis, as well as home phototherapy for psoriasis patients as a patient-centered therapy. The in-person discussion emphasized similar themes as well as personalized approaches to patient care. Integrating the results from the CER survey and group discussion as well as assessing the cost, feasibility, and resources available, three CER questions deemed to be of high priority on the research agenda were: 1) Are treatment outcomes different between psoriasis patients who are managed via a "treat-to-target" approach versus those who are not?
Conventional management for psoriasis and psoriatic arthritis involves starting a therapy and assessing for any kind of response, but without a certain target goal. Treating to a specific target level, also known as treat-to-target, is a disease-management approach that identifies a specific and well-defined treatment goal where frequent re-assessment occurs to evaluate whether treatment adjustment and/or escalation is required to achieve the predetermined goal.
A treat-to-target approach has been utilized with improved outcomes for several diseases, such as blood glucose control in diabetes, blood pressure targets in hypertension, lipid levels for heart disease, and remission or minimal disease goals in rheumatoid arthritis. 13, 14 However, data on strict glucose control in diabetes have demonstrated increased mortality 15 and consensus guidelines have determined insufficient support for lipid targets for cardiovascular disease, 16 calling into question the use of treat-to-target for these diseases. The ongoing controversy over treat-to-target in these diseases further strengthens the need to study this management approach and determine whether the adoption of treat-totarget is feasible and effective for psoriatic disease. Diseasespecific treat-to-target studies are particularly necessary, as outcomes and treatment targets are unique to each disease (i.e. quality of life in psoriasis vs. mortality in diabetes). Treatto-target approaches in psoriatic arthritis have suggested a state of minimal disease activity (MDA) as a reasonable goal for psoriatic arthritis, where several observational and RCT studies validated its feasibility to achieve an MDA state and its efficacy as it was associated with less joint damage progression and improved quality of life function. [17] [18] [19] [20] [21] Recently, the first-ever psoriasis treatment targets were published for use in the United States. 22 Measuring the effectiveness of these new treatment targets on improving patient outcomes was identified as high priority.
2) Are outcomes different for psoriasis patients who receive a screening questionnaire for psoriatic arthritis compared to psoriasis patients who don't receive a screening questionnaire?
Early diagnosis for psoriatic arthritis allows for earlier treatment initiation, which has been shown to prevent joint damage and slow disease progression, ultimately improving patient outcomes. 23 
Psoriasis Epidemiology Screening Tool (PEST), and Early
Arthritis for Psoriatic Patients (EARP). 24, 25 Sensitivities and specificities of questionnaires are well documented, 24, 25 and studies comparing the effectiveness of questionnaire use to current standard of care at reducing delay in psoriatic arthritis diagnosis were identified as high priority.
3) For people with skin similar to mine, is treatment with home-based phototherapy as effective and safe as officebased phototherapy?
Home-based phototherapy for psoriasis was first reported in a 1979 Swedish study. 26 The initiation of home-based phototherapy addresses patient-centered issues such as desire for treatment with no risks of internal side effects, preference for treatments which can be used safely in pregnancy and lactation, need for convenience, time constraints, cost of travel, and loss of income, 27 which may be especially important for patients with extensive disease requiring frequent visits or specific age groups that have limited available free time or transportation barriers. Our prior work has indicated a strong preference for use of officebased phototherapy by dermatologists, whereas surveys of NPF psoriasis patients treated by dermatologists (N=1451) suggests a strong preference for phototherapy delivered in the home. 9, 28 Studies in the Netherlands have reported similar effectiveness, lower burden of treatment, improved adherence, no increase in acute adverse events and greater 
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CONCLUSION
The first NPF Patient-Centered Research meeting was a productive and insightful experience for all stakeholders.
During the meeting, CER priorities were identified through the collaboration of researchers and patients as we outlined strategies to improve the platform in the future, including technology updates, better marketing, and improved patient outreach. Limitations to the survey include a risk of responder bias and answer/outcomes being dependent on the questions proposed. Nevertheless, the discussion and ideas developed have created a roadmap for research initiatives and will be used for future research proposals.
Effective dialogue regarding strategies to enhance patientcentered research efforts also was discussed to increase participation, especially among diverse groups, and improve advocacy and awareness. 
